Related Experiment Video
Updated: Jun 14, 2026
09:14
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan1, Susan Fotheringham, Victoria Wood
1Laboratory of Cancer Biology, Medical Sciences Division, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Summary
HR23B influences cancer cell sensitivity to histone deacetylase (HDAC) inhibitors. This study shows HR23B predicts clinical response in cutaneous T-cell lymphoma (CTCL), supporting personalized cancer medicine.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Biomarkers
Background:
- Histone deacetylase (HDAC) inhibitors are emerging cancer therapeutics.
- HR23B has been identified as a potential cancer biomarker influencing drug sensitivity.
- HDAC inhibitors are clinically used for cutaneous T-cell lymphoma (CTCL).
Purpose of the Study:
- To investigate the role of HR23B in CTCL.
- To determine if HR23B influences CTCL cell sensitivity to HDAC inhibitors.
- To assess HR23B as a predictive biomarker for clinical response to HDAC inhibitors in CTCL.
Main Methods:
- Evaluation of HR23B's role in CTCL cell lines.
- Analysis of proteasome activity in HDAC inhibitor-treated CTCL cells.
- Correlation of HR23B expression with clinical response in CTCL patient biopsies from a Phase II trial.
Main Results:
- HR23B expression levels dictate CTCL cell sensitivity to HDAC inhibitors.
- HDAC inhibitors disrupt proteasome activity in a HR23B-dependent manner.
- HDAC inhibitors enhance CTCL cell sensitivity to proteasome inhibitors.
- A strong correlation was observed between HR23B expression and clinical response to HDAC inhibitors in CTCL patients.
Conclusions:
- HR23B is a key regulator of HDAC inhibitor sensitivity in CTCL.
- HR23B serves as a predictive biomarker for HDAC inhibitor treatment response in CTCL.
- These findings support a personalized medicine strategy for CTCL treatment, translating laboratory discoveries into clinical applications.
